Literature DB >> 16784992

High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.

Tae-Joong Kim1, Seung Bae Rho, Yoon-La Choi, Chel Hun Choi, Jeong-Won Lee, Duk-Soo Bae, Geunghwan Ahn, Je-Ho Lee, Byoung-Gie Kim.   

Abstract

Tissue inhibitors of metalloproteinases (TIMPs) play key roles in maintaining homeostasis of the extracellular matrix by controlling matrix metalloproteinases (MMPs). In addition to their role in regulating MMPs, TIMPs have also been shown to have pluripotential effects on cell growth, apoptosis, and differentiation. The aim of this study was to evaluate TIMP-2 level in serous ovarian tumor tissues and to understand further the role of TIMP-2 protein in ovarian tumorigenesis. The expression of TIMP-2 was assessed by immunohistochemistry in a total of 57 ovarian specimens, including 5 normal ovaries, 12 benign serous cystadenomas, 20 serous borderline tumors, and 20 serous carcinomas. In addition, we transfected a TIMP-2 plasmid into the gynecologic cancer cell lines SKOV-3, 2774, and HeLa and then assayed cell growth, apoptosis, and MMP-2 activation. We found that TIMP-2 immunostaining was significantly more frequent in serous carcinomas, mainly in tumor epithelium, compared with cells of the other tissues studied. Tissue inhibitor of metalloproteinase-2 overexpression in ovarian cancer cells did not mediate proapoptosis, inhibited cisplatin-induced apoptosis, and induced MMP-2 expression. These findings suggest that TIMP-2 may function to favor tumor growth in serous ovarian tumorigenesis. Additional research is now needed to elucidate further the role of TIMP-2 in the biologic behavior of ovarian serous tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16784992     DOI: 10.1016/j.humpath.2006.02.017

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.

Authors:  Amer K Karam; Chintda Santiskulvong; Mirela Fekete; Sara Zabih; Carol Eng; Oliver Dorigo
Journal:  Cytoskeleton (Hoboken)       Date:  2010-08

2.  Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients.

Authors:  Agnieszka Hałoń; Ewa Nowak-Markwitz; Piotr Donizy; Rafal Matkowski; Adam Maciejczyk; Tserenchunt Gansukh; Balázs Györffy; Marek Spaczyński; Maciej Zabel; Hermann Lage; Pawel Surowiak
Journal:  J Histochem Cytochem       Date:  2012-04-17       Impact factor: 2.479

3.  Effects of an Engineered Anti-HER2 Antibody chA21 on Invasion of Human Ovarian Carcinoma Cell In Vitro.

Authors:  Yi Gao; Qiang Wu; Zheng-Sheng Wu; Gui-Hong Zhang; An-Li Zhang
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

4.  Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.

Authors:  Jean-Luc Brun; Annie Cortez; Bénédicte Lesieur; Serge Uzan; Roman Rouzier; Emile Daraï
Journal:  Oncol Rep       Date:  2011-12-22       Impact factor: 3.906

5.  Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer.

Authors:  Sherry W Yang; Diptiman Chanda; James J Cody; Angel A Rivera; Reinhard Waehler; Gene P Siegal; Joanne T Douglas; Selvarangan Ponnazhagan
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

6.  Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway.

Authors:  Bo Li; Shaoxi Cai; Yi Zhao; Qiyi He; Xiaodong Yu; Longcong Cheng; Yingfeng Zhang; Xiancheng Hu; Ming Ke; Sijia Chen; Misha Zou
Journal:  Oncotarget       Date:  2016-12-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.